AbbVie (ABBV) appears to be a compelling choice in the biotech sector, with a robust performance hinting towards a promising trajectory. Growth has been driven by their key immunology drugs,
Skyrizi and Rinvoq, despite the declining sales of blockbuster drug
Humira.
ABBV has surpassed earning and revenue estimates, contributing to a bullish performance. This outperformance led AbbVie to raise guidance for their pipeline drugs. Despite setbacks with its schizophrenia trials, positivity is seen with strategic acquisitions such as
Aliada Therapeutics and
Nimble Therapeutics, strengthening its outlook in Alzheimer's disease, immunology, and neuroscience. It is markedly active in collaborations, with deals like Xilio, focusing on developing novel tumor-activated immunotherapies.
ABBV also declared a
quarterly dividend, showing impressive shareholders' returns. However, the firm had to adjust its 2024 profit forecast due to the costs associated with its acquisitions. Despite minor stock declines here and there, it quickly bounced back, making long-term investors bullish on ABBV.
Abbvie ABBV News Analytics from Mon, 09 Sep 2024 07:00:00 GMT to Fri, 21 Feb 2025 10:38:47 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor -2
